Display options
Cite
Mammon K, Keshet R, Savion S, et al. Diabetes-induced fetal growth retardation is associated with suppression of NF-kappaB activity in embryos. Rev Diabet Stud. 2005;2(1):27-34doi: 10.1900/RDS.2005.2.27.
Mammon, K., Keshet, R., Savion, S., Pekar, O., Zaslavsky, Z., Fein, A., Toder, V., & Torchinsky, A. (2005). Diabetes-induced fetal growth retardation is associated with suppression of NF-kappaB activity in embryos. The review of diabetic studies : RDS, 2(1), 27-34. https://doi.org/10.1900/RDS.2005.2.27
Mammon, Keren, et al. "Diabetes-induced fetal growth retardation is associated with suppression of NF-kappaB activity in embryos." The review of diabetic studies : RDS vol. 2,1 (2005): 27-34. doi: https://doi.org/10.1900/RDS.2005.2.27
Mammon K, Keshet R, Savion S, Pekar O, Zaslavsky Z, Fein A, Toder V, Torchinsky A. Diabetes-induced fetal growth retardation is associated with suppression of NF-kappaB activity in embryos. Rev Diabet Stud. 2005;2(1):27-34. doi: 10.1900/RDS.2005.2.27. Epub 2005 May 10. PMID: 17491656; PMCID: PMC1762494.
Copy Download .nbib Format: NLM
Share it on

Rev Diabet Stud. 2005;2(1):27-34. doi: 10.1900/RDS.2005.2.27. Epub 2005 May 10.

Diabetes-induced fetal growth retardation is associated with suppression of NF-kappaB activity in embryos.

The review of diabetic studies : RDS

Keren Mammon, Rotem Keshet, Shoshana Savion, Olga Pekar, Zeev Zaslavsky, Amos Fein, Vladimir Toder, Arkady Torchinsky

Affiliations

  1. Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel.

PMID: 17491656 PMCID: PMC1762494 DOI: 10.1900/RDS.2005.2.27

Abstract

BACKGROUND: Mechanisms underlying diabetes-induced fetal growth retardation remain largely undefined. Two events such as the persistent activation of apoptosis or suppression of cell proliferation in embryos might directly result in fetal growth retardation. Evidence implicating the transcription factor NF-kappaB in the regulation of the physiological and teratogen-induced apoptosis as well as cell proliferation suggests that it may be a component of mechanisms underlying this pathology. To address this issue, this study was designed to test: 1) whether diabetes-induced fetal growth retardation is preceded by the modulation of NF-kappaB activity in embryos at the late stage of organogenesis and 2) whether apoptosis is altered in these embryos.

METHODS: The embryos and placentas of streptozotocin-induced diabetic mice collected on days 13 and 15 of pregnancy were used to evaluate the expression of NF-kappaB, IkappaBalpha and phosphorylated (p)-IkappaBalpha proteins by Western blot analysis and NF-kappaB DNA binding by an ELISA-based method. The detection of apoptotic cells was performed by the TUNEL assay and the expression of a proapoptotic protein Bax was evaluated by the Western blot.

RESULTS: The embryos of diabetic mice were significantly growth retarded, whereas the placental weight did not differ in diabetic or control females. Levels of NF-kappaB and p-IkappaBalpha proteins as well as the amount of NF-kappaB DNA binding was lower in embryos of diabetic mice as compared to those in controls. However, neither excessive apoptosis nor an increased Bax expression was found in growth-retarded embryos and their placentas.

CONCLUSION: The study herein revealed that diabetes-induced fetal growth retardation is associated with the suppression of NF-kappaB activity in embryos, which seems to be realized at the level of IkappaB degradation.

References

  1. Arch Physiol Biochem. 2001 Jul;109(3):260-71 - PubMed
  2. Diabetes. 2003 Jan;52(1):1-8 - PubMed
  3. Annu Rev Immunol. 2000;18:621-63 - PubMed
  4. Am J Reprod Immunol. 2004 Feb;51(2):138-43 - PubMed
  5. Oncogene. 1999 Nov 22;18(49):6845-52 - PubMed
  6. Diabetes. 1997 Jul;46(7):1189-97 - PubMed
  7. Reproduction. 2003 Apr;125(4):527-34 - PubMed
  8. Am J Reprod Immunol. 1995 Nov;34(5):288-98 - PubMed
  9. Diabetes. 1991 Dec;40 Suppl 2:94-8 - PubMed
  10. Biol Reprod. 2000 Sep;63(3):879-86 - PubMed
  11. Life Sci. 1995 Feb 17;56(13):1127-34 - PubMed
  12. Curr Pharm Des. 2004;10(23):2827-37 - PubMed
  13. Mol Pharmacol. 2004 Sep;66(3):404-12 - PubMed
  14. Semin Perinatol. 2002 Jun;26(3):190-5 - PubMed
  15. BMC Dev Biol. 2002;2:2 - PubMed
  16. Am J Pathol. 2001 Aug;159(2):387-97 - PubMed
  17. Dev Dyn. 2002 Oct;225(2):186-94 - PubMed
  18. Oncogene. 1999 Nov 22;18(49):6853-66 - PubMed
  19. Nature. 1995 Jul 13;376(6536):167-70 - PubMed
  20. Early Pregnancy. 1997 Mar;3(1):27-33 - PubMed
  21. Oncogene. 2003 Dec 8;22(56):8961-82 - PubMed
  22. J Mol Med (Berl). 2004 Jul;82(7):434-48 - PubMed
  23. J Pharmacol Exp Ther. 2002 Apr;301(1):277-83 - PubMed
  24. Brain Res. 2005 Mar 10;1037(1-2):12-24 - PubMed
  25. Diabetes Res Clin Pract. 2005 Feb;67(2):110-8 - PubMed
  26. Am J Reprod Immunol. 2003 Mar;49(3):159-68 - PubMed
  27. Am J Obstet Gynecol. 2005 Mar;192(3):967-72 - PubMed
  28. Trends Endocrinol Metab. 2001 Mar;12(2):78-82 - PubMed
  29. Pharmacol Toxicol. 1998 Sep;83(3):104-11 - PubMed
  30. Am J Pathol. 2000 Mar;156(3):1025-32 - PubMed
  31. Cell. 1998 Sep 18;94(6):695-8 - PubMed
  32. Nat Immunol. 2002 Mar;3(3):221-7 - PubMed
  33. Eur J Obstet Gynecol Reprod Biol. 2003 Sep 22;110 Suppl 1:S99-107 - PubMed
  34. Teratology. 1996 Oct;54(4):171-82 - PubMed
  35. Diabetologia. 2004 Dec;47(12):2072-80 - PubMed
  36. Diabetologia. 2004 Jan;47(1):132-9 - PubMed
  37. Nat Med. 1998 Dec;4(12):1421-4 - PubMed
  38. Teratog Carcinog Mutagen. 2000;20(2):73-86 - PubMed
  39. Clin Exp Pharmacol Physiol. 2004 Mar;31(3):119-28 - PubMed
  40. Early Hum Dev. 2001 Jan;60(3):207-14 - PubMed

Publication Types